Hot COVID-19
Home >Products> Microarrays | Software >Spotters / Scanning Apparatus> CapitalBio SmartArrayer 136 Microarray Spotter
Microarrays | Software:  Biochip   Spotters / Scanning Apparatus   Biology Software  
CapitalBio SmartArrayer 136 Microarray Spotter
CapitalBio SmartArrayer 136 Microarray Spotter
Place of Origin:
CapitalBio Corporation
  • Product Detail
  • Company Profile

    Designed for large-scale microarray printing of up to 136 slides simultaneously. Equipped with both contact printing and proprietary non-contact dispensing. Advanced environment control with filtered air and humidity control.
    CapitalBio Corporation was established on September 30, 2000. After 17 years of development, it now consists of five research institutes and five subsidiaries. The five research institutes are: Research Institute of Translational Medicine, Research Institute of Bioinformatics, Research Institute of Engineering, Research Institute of Health Science, and Research Institute of Health Technology. The five subsidiaries are: CapitalBio Technology Co., Ltd., CapitalBio Diagnostic Laboratory, CapitalBio eHealth Science & Technology (Beijing) Co., Ltd., CapitalBio Genomics Co., Ltd. and CapitalBio New View Diagnostic Technology Co., Ltd..

    CapitalBio Corporation is a leading provider of life science solutions. It provides products and services in the fields of clinical diagnostics, scientific research, HLA typing, animal disease control, food safety testing, identification of traditional Chinese herbs, molecular breeding, NIPT, and liquid biopsy. It possesses more than 125,000m2 of R&D, production, operation, and service facilities.

    CapitalBio Corporation possesses well-established quality management system. It is ISO 9001 and ISO 13485 certified. Its products are approved by China FDA and FDA in some other countries and are certified with appropriate CE, TUV/GS, and cTUVus certificates. Its lab is ISO17025 Certified and its HLA Typing Lab is ASHI certified.

    Innovation drives CapitalBio Corporation's continuous growth in the Life Science technology field. By September 30, 2016, CapitalBio Corporation has made 272 applications for patens all over the world, most of which have been approved. The conversion rate of CapitalBio Corporation’s patents is as high as 56.8%. CapitalBio Corporation has built a strong reputation for R & D of biochip related instruments and its products have been awarded numerous prizes.

    CapitalBio Corporation has established strategic partnerships with many life science companies in the world, as well as with distributors and dealers worldwide. It has offices in Hong Kong and the USA and its products have entered the clinical and research markets in more than 30 countries and regions.
Request Infomation
Request Infomation: yes no
Request Quotation: yes no

I agree to share my inquiry with the other matching suppliers.

Request Infomation

* Name:
Job Title:
* Tel:
* E-mail:
* Country:
Request Infomation:
yes no
Request Quotation:
yes no
* Message:
* Verification Code:
I agree to share my inquiry to the other matching suppliers.